ArticleAsia Pacific allergy2025
Assessment of the quality of life in patients with atopic dermatitis using the Kazakh version of the questionnaire "Dermatology Life Quality Index".
Article in Asia Pacific allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of the Dermatology Life Quality Index (DLQI), translated into Kazakh, for assessing the quality of life of patients with atopic dermatitis (AD) in Kazakhstan, has not yet been evaluated. Objective: The aim of the study is to assess the reliability and validity of the Kazakh language DLQI as a tool for assessing the quality of life of patients with AD. Methods: This multicenter study involved 883 adult patients of the Kazakh population diagnosed with AD. To assess the quality of life of AD patients, the DLQI questionnaire translated into Kazakh was used. Results: The reliability (Cronbach Conclusion: The results demonstrate that the Kazakh language version of the DLQI is a reliable and valid tool for measuring the impact of AD on quality of life. Its applicability in research and clinical settings underscores its versatility. The study underscores the significance of clinical and demographic characteristics, along with the quality of life, for an accurate assessment of disease severity and effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.